Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-Infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART).

Next Previous
Search
Trial Profile

Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-Infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary)
  • Indications Heart failure; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms VCU-ART

Most Recent Events

  • 13 Nov 2023 Results assessing sex-based differences in the systemic inflammation (CRP levels) and composite end-point of new-onset HF or death in patients with STEMI from three different Virginia Commonwealth University Anakinra Response Trial (VCU-ART) randomized clinical trials VCU-ART, VCU-ART-2 & VCU-ART-3 presented at the American Heart Association Scientific Sessions 2023.
  • 28 Aug 2023 Results assessing role of diabetes mellitus as a modulating factor in respect to the efficacy of anakinra treatment during the first 14 days after STEMI presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 18 Nov 2019 Results (n=63) assessing data from anakinra groups for 14 days after STEMI were presented at the American Heart Association Scientific Sessions 2019

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top